Home›Clinical trials›Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

A study testing whether a GLP-1 medicine, semaglutide, can help people drink less.

Recruiting now. Registry record last updated August 12, 2026.

Who can join
Adults 18 to 80, have alcohol use disorder, BMI 21+.
What you take
semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 3.7 years; your own time in it is usually shorter.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 3Sponsor VA Office of Research and DevelopmentDrug semaglutideClass GLP-1 RASites 19 USEnrollment target 622

What this study is for

Primary condition: Alcohol Use Disorder.

Full scientific study title: Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE).

Who can join

Age18 to 80SexAnyBMI21 or higher

Adults 18 to 80, have alcohol use disorder, BMI 21+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Veteran
  • WHO risk drinking level of Very High or High in the 28 days prior to screening (based on screening TLFB)
  • Current diagnosis of moderate or severe AUD (i.e., meeting at least 4 of 11 DSM-5 AUD criteria) based on semi-structured diagnostic exam (MINI)
  • Able and willing to provide informed consent
  • Has a desire to reduce their alcohol consumption

Key exclusion criteria

  • Medical History (medical history form)
  • Type 1 diabetes
  • History of acute or chronic pancreatitis
  • History of diabetic ketoacidosis
  • History of proliferative diabetic retinopathy

Where this trial is enrolling

This trial has 19 sites across 14 states. Contact a site coordinator directly to start screening.

California3 sites
  • VA Long Beach Healthcare System, Long Beach, CA
    Long Beach, California
    Larry Albers, MD562-826-8000larry.albers@va.gov
  • VA Palo Alto Health Care System, Palo Alto, CA
    Palo Alto, California
    Michael J Ostacher, MD650-493-5000Michael.Ostacher@va.gov
  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA
    West Los Angeles, California
    Zhaoping Li, MD310-268-3528zhaoping.li@va.gov
Florida1 site
  • Orlando VA Healthcare System, Orlando, FL
    Orlando, Florida
    Ishak Mansi, MD407-631-4011Ishak.mansi@va.gov
Georgia1 site
  • Atlanta VA Medical and Rehab Center, Decatur, GA
    Decatur, Georgia
    Mary Rhee, MD404-321-6111mary.rhee@va.gov
Illinois1 site
  • Edward Hines Jr. VA Hospital, Hines, IL
    Hines, Illinois
    Alma Ramic, MD708-202-8387alma.ramic2@va.gov
Michigan1 site
Minnesota1 site
  • Minneapolis VA Health Care System, Minneapolis, MN
    Minneapolis, Minnesota
    Eric Dieperink, MD6124671580Eric.Dieperink@va.gov
North Carolina2 sites
  • Asheville VA Medical Center, Asheville, NC
    Asheville, North Carolina
    Brandon Corbett, MD8282987911brandon.corbett@va.gov
  • Durham VA Medical Center, Durham, NC
    Durham, North Carolina
    Daniel Blalock, MDDaniel.Blalock@va.gov
Ohio1 site
  • Louis Stokes VA Medical Center, Cleveland, OH
    Cleveland, Ohio
    Michael Ignatowski, MD216-231-3241
Oregon1 site
  • VA Portland Health Care System, Portland, OR
    Portland, Oregon
    Kyle Sears, MD503-273-5108kyle.sears@va.gov
Pennsylvania2 sites
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
    Philadelphia, Pennsylvania
    David W Oslin, MD(215) 823-5894Dave.Oslin@va.gov
  • Corporal Michael J. Crescenz VA Medical Center
    Philadelphia, Pennsylvania
    Kyle Kampman, MD2158235800kyle.kampman@va.gov
Texas2 sites
  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
    Dallas, Texas
    Kyaw Soe, MD214-857-0125kyaw.soe@va.gov
  • Michael E. DeBakey VA Medical Center, Houston, TX
    Houston, Texas
    Christopher Verrico, PhD713-798-7658Christopher.verrico@va.gov
Utah1 site
  • VA Salt Lake City Health Care System, Salt Lake City, UT
    Salt Lake City, Utah
    Adam Gordon, MD385-297-0370adam.gordon@va.gov
Washington1 site
Wisconsin1 site
  • William S. Middleton Memorial Veterans Hospital, Madison, WI
    Madison, Wisconsin
    Timothy Juergens, MD608-280-7084Timothy.juergens@va.gov

Timeline

Started enrolling: July 28, 2026. Expected completion: March 30, 2030. Last updated on ClinicalTrials.gov: August 12, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.